Patents by Inventor Thomas Mikita

Thomas Mikita has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11066481
    Abstract: In one aspect, antibodies, or antigen-binding fragments thereof, that specifically bind to activated Factor XI (FXIa) are provided. Also provided are methods of obtaining such antibodies and nucleic acids encoding the same. In another aspect, compositions and therapeutic prevention of thrombotic diseases, disorders or conditions are provided. In another aspect, anti-idiotype antibodies that bind anti-FXIa antibodies of the disclosure, as well as compositions comprising the anti-idiotype antibodies, methods of obtaining the antibodies and nucleic acids encoding the same, are also provided.
    Type: Grant
    Filed: July 22, 2016
    Date of Patent: July 20, 2021
    Assignees: The Regents of the University of California, Pfizer, Inc.
    Inventors: Thomas Mikita, Lauren K. Ely, Huilan Gao, Yun Kim, Isaac J. Rondon, Tovo David, Shaun R. Coughlin
  • Publication number: 20200095334
    Abstract: In one aspect, antibodies, or antigen-binding fragments thereof, that specifically bind to activated Factor XI (FXIa) are provided. Also provided are methods of obtaining such antibodies and nucleic acids encoding the same. In another aspect, compositions and therapeutic prevention of thrombotic diseases, disorders or conditions are provided. In another aspect, anti-idiotype antibodies that bind anti-FXIa antibodies of the disclosure, as well as compositions comprising the anti-idiotype antibodies, methods of obtaining the antibodies and nucleic acids encoding the same, are also provided.
    Type: Application
    Filed: July 22, 2016
    Publication date: March 26, 2020
    Inventors: Thomas MIKITA, Lauren K. ELY, Huilan GAO, Yun KIM, Isaac J. RONDON, Tovo DAVID, Shaun R. COUGHLIN
  • Publication number: 20180216094
    Abstract: The disclosure provides compositions and methods for counteracting the effects of direct activated Factor XI (FXIa) inhibitors in a subject by administering a variant of FXIa.
    Type: Application
    Filed: July 22, 2016
    Publication date: August 2, 2018
    Inventors: Thomas MIKITA, Lauren K. ELY, Tovo DAVID, Shaun R. COUGHLIN
  • Publication number: 20030194721
    Abstract: The invention relates to isolated polynucleotides, purified polypeptides, and compositions comprising pluralities of polynucleotides that are differentially expressed when foam cells are treated with oxidized low-density lipoprotein and LPS as associated with atherosclerosis. The invention also presents the use of the polynucleotides as elements on a substrate and provides methods for using the polynucleotides and polypeptides.
    Type: Application
    Filed: September 18, 2002
    Publication date: October 16, 2003
    Applicant: Incyte Genomics, Inc.
    Inventors: Thomas Mikita, Dov Shiffman, J. Gordon Porter, Matthew R. Kaser
  • Publication number: 20030165924
    Abstract: The present invention relates to purified polynucleotides and compositions comprising pluralities of polynucleotides that are differentially expressed during foam cell development and are associated with atherosclerosis. The present invention presents the use of the compositions as elements on a substrate, and provides methods for using the compositions and polynucleotides.
    Type: Application
    Filed: October 4, 2002
    Publication date: September 4, 2003
    Inventors: Dov Shiffman, Roland Somogyi, Richard Lawn, Jeffrey J. Seilhamer, J. Gordon Porter, Thomas Mikita, Julie Tai